Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies.

Drug Design, Development and Therapy
Nathan W KopperDaniel J Thompson

Abstract

Vasomotor symptoms (VMS) associated with menopause can cause significant discomfort and decrease the quality of life for women in the peri-menopausal and post-menopausal stages of life. Hormone therapy (HT) is the mainstay of treatment for menopausal symptoms and is currently the only therapy proven effective for VMS. Numerous HT options are available to treat VMS, including estrogen-only and estrogen-progestogen combination products to meet the needs of both hysterectomized and nonhysterectomized women. In addition to selecting an appropriate estrogen or estrogen-progestogen combination, consideration should be given to the route of administration to best suit the needs of the patient. Delivery systems for hormone therapy include oral tablets, transdermal patches, transdermal topical (nonpatch) products, and intravaginal preparations. Oral is currently the most commonly utilized route of administration in the United States. However, evidence suggests that oral delivery may lead to some undesirable physiologic effects caused by significant gut and hepatic metabolism. Transdermal drug delivery may mitigate some of these effects by avoiding gut and hepatic first-pass metabolism. Advantages of transdermal delivery include the abil...Continue Reading

References

Nov 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J R McNamaraE J Schaefer
Sep 12, 1991·The New England Journal of Medicine·M J StampferC H Hennekens
Jun 19, 1986·The New England Journal of Medicine·R J ChetkowskiH L Judd
Oct 24, 1985·The New England Journal of Medicine·M J StampferC H Hennekens
Sep 1, 1995·American Journal of Obstetrics and Gynecology·L E Nachtigall
Feb 1, 1995·Obstetrics and Gynecology·D GradyD Petitti
Jun 1, 1994·Current Opinion in Lipidology·F M Sacks, B W Walsh
Dec 1, 1993·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·C CampagnoliP Sismondi
Aug 15, 1996·The New England Journal of Medicine·F GrodsteinC H Hennekens
Dec 9, 1997·British Journal of Obstetrics and Gynaecology·E HirvonenG Wilén-Rosenqvist
Apr 16, 1998·Acta Obstetricia Et Gynecologica Scandinavica·C E BondukiG R Lima
Mar 3, 2001·American Journal of Obstetrics and Gynecology·R Ansbacher
Aug 31, 2001·Menopause : the Journal of the North American Menopause Society·J KayserA Pressman
Mar 26, 2002·Climacteric : the Journal of the International Menopause Society·J Y ReginsterR Lins
May 17, 2002·American Journal of Obstetrics and Gynecology·Sven O SkoubyJørgen Jespersen
Jul 2, 2002·JAMA : the Journal of the American Medical Association·Deborah GradyUNKNOWN HERS Research Group
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Aug 21, 2002·Annals of Internal Medicine·Linda L HumphreyHarold C Sox
Feb 13, 2003·JAMA : the Journal of the American Medical Association·Joan Stephenson
Mar 11, 2003·Menopause : the Journal of the North American Menopause Society·UNKNOWN North American Menopause Society
Apr 23, 2003·Journal of the American College of Cardiology·Wanpen VongpatanasinIshwarlal Jialal
Jul 24, 2003·Thrombosis and Haemostasis·Karine LacutUNKNOWN SARAH Investigators
Aug 21, 2003·Lancet·Pierre-Yves ScarabinUNKNOWN EStrogen and THromboEmbolism Risk Study Group
Nov 25, 2003·Menopause : the Journal of the North American Menopause Society·David F Archer, UNKNOWN EstroGel Study Group
Jan 8, 2004·JAMA : the Journal of the American Medical Association·Adam L HershRandall S Stafford
Apr 15, 2004·JAMA : the Journal of the American Medical Association·Garnet L AndersonUNKNOWN Women's Health Initiative Steering Committee
Jul 31, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Aamer AbbasWanpen Vongpatanasin
Aug 5, 2004·The Annals of Pharmacotherapy·Susan E Fugate, Chelsea O Church
Oct 2, 2004·Obstetrics and Gynecology·UNKNOWN American College of Obstetricians and Gynecologists Women's Health Care Physicians
Nov 16, 2004·Endocrine·Rogerio A Lobo

❮ Previous
Next ❯

Citations

Feb 8, 2014·Journal of Obstetric, Gynecologic, and Neonatal Nursing : JOGNN·Heidi Collins Fantasia, Melissa A Sutherland
Aug 8, 2018·Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences·Mireille Hildebrandt
Mar 10, 2016·Menopause : the Journal of the North American Menopause Society·James A SimonPatrick Lefebvre
Apr 12, 2019·International Journal of Environmental Research and Public Health·Lucia LanciottiSusanna Esposito
May 6, 2021·Menopause : the Journal of the North American Menopause Society·Johanna E LummeMaarit Niinimäki

❮ Previous
Next ❯

Methods Mentioned

BETA
Replacement

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Menopause : the Journal of the North American Menopause Society
J Christopher Gallagher, Jeffrey P Levine
Menopause : the Journal of the North American Menopause Society
Saranya WattanakumtornkulDaniel B Williams
© 2022 Meta ULC. All rights reserved